Stomach Cancer

• EMA approval · 2026-01-28
  EMA Authorised: Herzuma (trastuzumab) — Celltrion Healthcare Hungary Kft.

  The EMA authorised Herzuma, a trastuzumab biosimilar from Celltrion Healthcare Hungary Kft, for stomach cancer and breast cancer in the EU.

• EMA approval · 2026-01-19
  EMA Authorised: Zercepac (trastuzumab) — Accord Healthcare S.L.U.

  The EMA authorised Zercepac, a trastuzumab biosimilar from Accord Healthcare S.L.U., for breast cancer and stomach cancer.

• EMA approval · 2025-10-30
  EMA Authorised: Teysuno (tegafur;gimeracil;oteracil) — Nordic Group B.V.

  The EMA authorised Teysuno, a fixed-dose combination of tegafur, gimeracil and oteracil, for stomach cancer. The marketing authorisation hol…

• EMA approval · 2025-05-05
  EMA Authorised: Capecitabine Accord (capecitabine) — Accord Healthcare S.L.U.

  The EMA authorised Capecitabine Accord (capecitabine) by Accord Healthcare S.L.U. for breast cancer, colorectal cancer, and stomach cancer, …

• FDA approval · 2016-02-17
  FDA Approved: FLUOROURACIL — Original Application (Sagent Pharmaceuticals)

  FDA approves an Original Application for Fluorouracil from Sagent Pharmaceuticals, establishing a generic injectable form of the chemotherap…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA approval · 2007-04-26
  FDA Approved: FLUOROURACIL — Original Application (Accord Healthcare, Inc.)

  FDA approved Accord Healthcare’s original application for Fluorouracil as a generic injectable chemotherapy agent for multiple cancers.